NEW YORK, May 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (NASDAQ:INSY) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased INSYS securities between February 23, 2016 and March 15, 2017, both dates inclusive (the "Class Period"). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/insy.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) as a result, INSYS lacked effective internal controls over financial reporting; and (4) consequently, the Company’s public statements were materially false and misleading at all relevant times.
On March 15, 2017, after-market hours, INSYS announced that it postponed filing its financial results for the quarter and year ended December 31, 2016. INSYS told investors that “[t]he Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016.” Following this news, INSYS stock dropped $0.49 per share, or 4.64%, to close at $10.06 on March 16, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/insy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Apple Turns 50: From Garage Startup to AI Crossroads
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



